This study tests whether adding the experimental drug LAM561 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 144 adults aged 18 to 75 will receive either LAM561 or a placebo alongside their usual treatmen…
Phase: PHASE2, PHASE3 • Sponsor: Laminar Pharmaceuticals • Aim: Disease control
Last updated May 01, 2026 15:57 UTC